Omalizumab

證據等級: L5

預測適應症: 10 個

Omalizumab: From Allergic Asthma/Urticaria to Bronchitis

One-Sentence Summary

Omalizumab (Xolair) is a humanized anti-IgE monoclonal antibody whose established use, per the literature captured in this evidence pack, is moderate-to-severe allergic asthma and chronic spontaneous urticaria (CSU); a formal Danish/DrugBank-verified original indication record is not yet available. The TxGNN model predicts a new use in Bronchitis, but the 2 clinical trials and 8 publications currently attached to this candidate consist almost entirely of asthma data, and the model’s own rationale flags this as a likely disease-label/ontology mismatch rather than direct bronchitis evidence.

Quick Overview

Item	Content
Original Indication	Not registered in Denmark; internationally indicated for moderate-to-severe allergic asthma and chronic spontaneous urticaria (per literature in this pack)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.9992%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

A structured mechanism-of-action record from DrugBank is currently flagged as a data gap in this pack (DG002). However, the attached literature is itself informative: omalizumab is a recombinant humanized monoclonal antibody that binds free IgE and blocks its interaction with the high-affinity FcεRI receptor on mast cells and basophils, reducing downstream allergic airway inflammation (PMID 16222080, 11270941). This is the drug’s well-documented mechanism in allergic asthma.

On a purely pathophysiological basis, this mechanism could plausibly extend to airway conditions with an eosinophilic/allergic component, such as eosinophilic bronchitis, since chronic bronchitis and asthma share overlapping inflammatory pathways and frequently co-occur clinically.

However, this rationale should be read with caution. The model’s own repurposing_rationale explicitly notes that the trials and literature returned under the “bronchitis” label are almost entirely asthma studies (e.g., NCT02477332 is a Chronic Spontaneous Urticaria trial; the literature set includes reviews titled “Omalizumab in asthma” and “Adult asthma exacerbations”), with only one case report (PMID 31478531) tangentially referencing bronchitis via a post-procedural complication. This pattern suggests a likely knowledge-graph node overlap between “bronchitis” and “asthma” rather than a genuine, independently supported repurposing signal for bronchitis itself.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02049294	Phase 2/3	Completed	11	Steroid-sparing effect of omalizumab in patients with asthma and persistent eosinophilic bronchitis; very small sample (relevance grade B — actual population is asthma + eosinophilic bronchitis, not bronchitis alone)
NCT02477332	Phase 2	Completed	382	Dose-finding study of QGE031 (ligelizumab, an anti-IgE agent related to omalizumab) as add-on therapy in Chronic Spontaneous Urticaria — disease population does not match bronchitis (relevance grade C)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16222080	2005	Review	Clinical reviews in allergy & immunology	Overview of omalizumab approval and post-approval experience; efficacy established in moderate-to-severe persistent asthma, not bronchitis
21121874	2011	Cohort/Safety Study	Current medical research and opinion	Pooled safety analysis of omalizumab in children with allergic (IgE-mediated) asthma
35369622	2022	Cohort	Postepy dermatologii i alergologii	Omalizumab in older patients with severe allergic asthma-COPD overlap
30196731	2018	Review	Expert opinion on pharmacotherapy	Discusses smoking-induced airway diseases (chronic bronchitis, emphysema) as comorbid with asthma; not an omalizumab efficacy study in bronchitis
17663923	2007	Review	Allergologia et immunopathologia	General review of monoclonal antibody use in pediatrics; mentions anti-IgE therapy only in passing
21163396	2010	Review	Revue des maladies respiratoires	French expert review on adult asthma exacerbations; not bronchitis-specific
31478531	2019	Case Report	Journal of investigational allergology & clinical immunology	Rare case of plastic bronchitis following bronchial thermoplasty (a device procedure); no omalizumab treatment data
26466493	2015	Review	Masui (Japanese J. Anesthesiology)	Perioperative management review of asthma/chronic bronchitis patients; mentions omalizumab as an asthma option only

Denmark Market Information

Omalizumab currently has no marketing authorisations on record in this evidence pack (total_licenses: 0, market_status: 未上市/Not marketed), so no authorisation table can be populated. Note this reflects the data captured in this evidence pack — omalizumab (Xolair®) holds a centralised EU/EMA marketing authorisation for asthma, CSU, and chronic rhinosinusitis with nasal polyps in other jurisdictions; this should be independently confirmed against the Danish Medicines Agency (Laegemiddelstyrelsen) product register.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No structured warnings, contraindications, or drug-drug interaction data were returned for this candidate (DDI query status: not found).

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L3, and — more importantly — the trial and literature evidence attached to the “bronchitis” label is predominantly asthma-focused, indicating this may be a TxGNN disease-node/ontology mapping artifact rather than a validated, independent repurposing signal for bronchitis.
Two structural data gaps block further evaluation: DG001 (Blocking) — no local product label/warnings available, so a safety pre-screen (S1) cannot be completed; DG002 (High) — no confirmed mechanism-of-action record from DrugBank.
The drug itself has zero marketing authorisations recorded in Denmark, so there is no local regulatory foothold to build on.

To proceed, the following is needed:

Confirm whether the TxGNN “bronchitis” disease node is distinct from or conflated with “asthma” in the underlying knowledge graph before treating this as a novel candidate.
Obtain dedicated bronchitis-specific (not asthma-labeled) clinical evidence, ideally from a controlled trial in eosinophilic or chronic bronchitis populations.
Retrieve the TFDA/Danish SmPC warnings and contraindications (DG001) and a confirmed DrugBank mechanism-of-action record (DG002).
Given the same evidence pack contains a materially stronger, directly relevant candidate — “obstructive lung disease” (i.e., severe allergic asthma), which carries L1 evidence (multiple completed Phase 3 RCTs, e.g., NCT00314574, n=850) and a “Proceed with Guardrails” recommendation — that candidate should be evaluated separately as it appears to be the true source of the high-quality trial data currently misattributed to bronchitis.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.